Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren
Public ClinicalTrials.gov record NCT00441064. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label, Blinded Endpoint, Multi-center, Cross-over Study to Evaluate the Effect of High and Low Sodium Diets on Reduction in Mean 24-hour Ambulatory Blood Pressure in Systolic Hypertensive Patients Treated With Aliskiren (300 mg)
Study identification
- NCT ID
- NCT00441064
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Novartis
- Industry
- Enrollment
- 132 participants
Conditions and interventions
Conditions
Interventions
- Aliskiren Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2006
- Primary completion
- Oct 31, 2007
- Completion
- Oct 31, 2007
- Last update posted
- Mar 24, 2011
2007
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis US | Orangevale | California | — | — |
| Novartis US | Brooklyn Center | Minnesota | — | — |
| Novartis US | Butte | Montana | — | — |
| Novartis US | Missoula | Montana | — | — |
| Novartis US | Lincoln | Nebraska | — | — |
| Novartis US | Johnson City | New York | — | — |
| Novartis US | Asheboro | North Carolina | — | — |
| Novartis US | Shelby | North Carolina | — | — |
| Novartis US | Cincinnati | Ohio | — | — |
| Novartis US | Kettering | Ohio | — | — |
| Novartis US | Downington | Pennsylvania | — | — |
| Novartis US | Erie | Pennsylvania | — | — |
| Novartis US | Pittsburgh | Pennsylvania | — | — |
| Novartis US | Dallas | Texas | — | — |
| Novartis US | Kingsport | Texas | — | — |
| Novartis US | Bountiful | Utah | — | — |
| Novartis US | Salt Lake City | Utah | — | — |
| Novartis US | Port Orchard | Washington | — | — |
| Novartis US | Madison | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00441064, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 24, 2011 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00441064 live on ClinicalTrials.gov.